



Contact:

Intact Medical Corporation

Christopher Bleck, President and CEO
508-655-7820

Rx Communications Group

Paula Schwartz (investors) 917-322-2216
Tony Ho Loke (media) 917-322-2164

NEOTHERMIA CORPORATION CHANGES NAME TO INTACT MEDICAL CORPORATION AND RE-NAMES ITS BREAST BIOPSY PRODUCT LINE

New Name Leverages Strength of Product Line and Aligns Company and Products in a Single Brand Name

NATICK, MA, November 9, 2005 -- Neothermia Corporation, an emerging leader in minimally invasive systems for the diagnosis of breast cancer, today announced that, effective immediately, it has changed its name to Intact Medical Corporation. Concurrent with the name change, the Company has also re-named its FDA-approved breast biopsy system the **Intact**[™] Breast Lesion Excision System -- previously known as the **en-bloc**[™] Biopsy System.

Intact Medical Corporation has adopted these new corporate and product names to capitalize on the unique, clinically proven value of its products. In a survey conducted by the Company earlier this year, nearly *all* physicians indicated that they were overwhelmingly positive about the advantages of excising an *intact* breast lesion sample, compared to other methods of breast biopsy. By allowing physicians to extract the entire sample in a simple office procedure with the **Intact**[™] Breast Lesion Excision System, a diagnosis can be made quickly and accurately, often saving patients additional diagnostic surgeries, such as open surgical biopsy, to confirm a diagnosis.

Commenting on today's news, Christopher Bleck, President and Chief Executive Officer of Intact Medical Corporation said, "In conjunction with expanding our product and clinical development programs, we wanted a stronger corporate identity to more accurately reflect our Company and the value our products bring to the medical and patient communities." The **Intact**[™] Breast Lesion Excision System can frequently capture the *entire* lesion, while preserving the integrity of its intact architecture. This capability is invaluable to a broad spectrum of clinicians. Consequently, we are expanding our marketing efforts, permitting more physicians and patients to benefit from the distinct advantages of the **Intact**[™] Breast Lesion Excision System."

The **Intact**[™] Breast Lesion Excision System is a vacuum-assisted, image-guided procedure in which a slender wand is inserted through a small incision in the breast to remove an intact sample of suspicious tissue for histopathologic analysis. The procedure is performed under local anesthesia in an outpatient setting, with the actual capture of the breast lesion completed in less than 10 seconds. After the lesion is withdrawn, the incision is effectively closed with a bandage, requiring no stitches.



In August 2005, the FDA approved several expanded indications for the *Intact*[™] Breast Lesion Excision System, allowing its use to obtain tissue samples for histologic examination for the partial or complete removal of an imaged abnormality, or partial removal of a palpable abnormality that has been classified as benign. The approval was based on data showing that the device was equivalent to *Mammotome*[®] core biopsy when totally or partially removing an imaged abnormality. The use of the device to remove more intact tissue from the region of a suspicious lesion is expected to improve diagnostic accuracy compared with core biopsy and reduce the potential for procedural sampling error.

Along with the Company's name change, Intact Medical Corporation has adopted a new corporate identity, including a new logo and visual identity, and a new website that can be found at www.intactmedical.com. All future business activity will be undertaken with the new name.

About Intact Medical Corporation

Founded in 1998, and based in Natick, Massachusetts, Intact Medical Corporation is a privately held company focused on the design, development and marketing of innovative, minimally invasive systems for the volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets. The Company's lead product, the *Intact*[™] Breast Lesion Excision System, received market clearance from the Food and Drug Administration in June, 2001. Initial products are targeted at breast biopsy and the excision of benign lesions, potentially obviating the need for open surgical excisions. In August 2005, the company received expanded approval for the System, allowing its use to obtain tissue samples for histologic examination with partial or complete removal of an imaged abnormality, or partial removal of a palpable abnormality that has been classified as benign.

For more details on the corporate name change and the company's product family and services, visit www.intactmedical.com

###